Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects
about
Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infectionsHealthcare-associated infections, infection control and the potential of new antibiotics in development in the USANew trends in aminoglycosides use.Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.Investigational antimicrobial agents of 2013.Plazomicin: an investigational therapy for the treatment of urinary tract infections.Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.Pipeline of Known Chemical Classes of Antibiotics.A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosidesNew antibiotic agents in the pipeline and how they can help overcome microbial resistance.New and alternative approaches to tackling antibiotic resistance.In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.Antibiotics in development targeting protein synthesis.Aminoglycoside therapy in infectious diseases.Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.Current strategies for the treatment of complicated intraabdominal infections.Neutrophil gelatinase associated lipocalin in acute kidney injury.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.
P2860
Q26859978-589238BF-5601-4560-9F50-75D5EC946B18Q26995305-170729A4-30DE-449F-9A44-0DF14F9BB585Q33951177-8C9B23F2-9005-4A25-A9BE-511C9B981539Q34269044-2A143D4A-D1CC-47E4-A714-7675514B3B3DQ34375204-8AE948AB-6E7E-4F1D-A04B-6D05D871CB08Q34673393-B6297156-0B80-4F3C-962A-3A2755A9B74FQ36107990-7D4E4CE3-B4AD-406A-893C-591CF6BFADDEQ36683409-4904D98C-99F8-49CB-8A8E-67815604ACFFQ36726249-F71ED991-0F72-4A87-990E-3E8B1E56DCB9Q36845895-51BA3070-1527-4A35-88EB-3638631C72EAQ37372123-4CF1318E-ABEE-4307-B048-44CCB17561B8Q37712980-9AEA9598-791E-486C-8410-2ADFB143CF3BQ37970724-0943252E-DD19-4FB7-9CEB-B64C9CBB7C1AQ38112810-31708CF9-8E80-4671-8EEF-2D69A5D5F7C6Q38117380-673AC945-F573-49D4-B3B1-94B087B121B0Q38123247-4C2CC8E4-69B3-4F49-81AA-CC0B3169D424Q38160639-1AFF6038-D6D4-4973-9838-CD92768EEC86Q38262205-D44ABC30-4E3B-4F83-8C71-E27163E861BFQ38672016-81893AB5-E9A9-424C-A8C1-C07F3DA5A61EQ38783043-4181F3D6-BA02-496F-9251-314277D5754FQ38892589-B4D28F36-CC15-4000-A33E-7E1FA4A32F59Q49598865-1981C993-2D80-4C17-BF15-87AD48D21B6E
P2860
Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@ast
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@en
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@nl
type
label
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@ast
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@en
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@nl
prefLabel
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@ast
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@en
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and safety of ...... ravenously in healthy subjects
@en
P2093
Carter D Brooks
Jon B Bruss
Kenneth J Tack
Marie T Borin
Nancy A Havrilla
Robert T Cass
P2860
P304
P356
10.1128/AAC.00624-11
P407
P577
2011-09-12T00:00:00Z